SIRPA and neoplasm: However, mice receiving NDV-vectorized CD47 blockade had a higher incidence of CR compared to those receiving NDV alone, in addition to delayed tumor growth (Figures 6B and 6C); 66.7% (4/6) and 42.9% (3/7) of mice receiving NDV-αCD47 and NDV-SIRPα-Fc experienced CR, compared to 33.3% (2/6) in those receiving NDV alone (Figure 6B).